BioPharmSignal logoBioPharmSignal

Biotech News

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Ascendis Pharma (ASND)Ascendis PharmaCompany update

- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Simplified listing structure intended to enable enhanced depth and breadth of

Related news

ASNDAscendis Pharma2026-04-20 12:00 EST

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

ASNDAscendis Pharma2026-05-07 11:30 EST

Ascendis Pharma Reports First Quarter 2026 Financial Results

View all latest news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-08-13 11:30 EST

Ascendis Pharma Reports Second Quarter 2026 Financial Results

ASNDAscendis Pharma2026-08-06 20:01 EST

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

ASNDAscendis Pharma2026-08-06 12:00 EST

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

ASNDAscendis Pharma2026-06-30 12:30 EST

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

ASNDAscendis Pharma2026-06-26 20:01 EST

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Stock data

Close
253.29 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States